Health Condition 1: null- This study group consists of HIV positive Children in the age group (2-5 Years of age)
Conditions
Interventions
Intervention1: Vaccines used :
Pneumococcal Conjugate Vaccine (PCV-13 manufactured by Wyeth) and Hib Conjugate Vaccine (HibCV , manufactured by Serum Institute -India)
: Schedule :
â?¢ Two doses of
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1.Children 2-5 years of age known to have HIV infection with normal to moderate immune suppression who have not had the Hib or pneumococcal conjugate vaccine 2.HIV negative children of 2-5 years of age who have not had the pneumococcal or Hib conjugate vaccines 3.Adult household member of child vaccinee 4.Sibling of child vaccinee
Exclusion criteria
Exclusion criteria: 1. Hospitalized children, 2. Child who presents with an acute illness on study day requiring hospitalization or inpatient short stay observation will be excluded. 3. Children with severe immune suppression 4. Children with an acute febrile illness with fever over 38 degrees Celsius will be excluded for vaccine on that study day. 5. Known previous immunization with HibCV or PCV. 6. Known contraindication to HibCV or PCV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Nasopharyngeal carriage rate of Hib and Pneumococcus for all vaccine recipients, adult household member and sibling living with vaccine recipient 2.Serotypes of pneumococcus isolated 3. Reported adverse events to vaccine recipients Timepoint: Measured at baseline and at two month intervals in HIV infected children, HIV uninfected controls, their siblings and parents, for a follow-up time of one year since study entry. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Immune response to the HibCV and PCV based on ELISA 2. Antibiotic susceptibility of Hib and Pneumococcal isolates 3. Carriage rates of other co-colonizers in the nasopharynx specifically S. aureus Timepoint: Measured at baseline and at two month intervals in HIV infected children, HIV uninfected controls, their siblings and parents, for a follow-up time of one year since study entry. | — |
Countries
India
Contacts
Public ContactDr Subhashish Bhattacharya
School of Medical Science and Technology , Indian Institute of Technology â??Kharagpur
Outcome results
None listed